Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Stock Moves -0.37%: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $82.63, marking a -0.37% move from the previous day.

Glaxo's Zejula Gets Positive CHMP View for First-Line Setting

by Zacks Equity Research

The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.

Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival

by Zacks Equity Research

Seattle Genetics' (SGEN) phase III EV-301 study on Padcev meets the main goal of overall survival compared to chemotherapy in patients previously treated for locally advanced/metastatic urothelial cancer.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals

by Kinjel Shah

AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.

Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe

by Zacks Equity Research

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.

Bristol-Myers' Opdivo+Yevroy Application Gets EMA Validation

by Zacks Equity Research

Bristol Myers Squibb (BMY) gets EMA validation for a type II variation application for its Opdivo+Yervoy combination to treat previously untreated, unresectable malignant pleural mesothelioma.

Lilly Drug Gets Fast Track to Improve Heart Attack Outcome

by Zacks Equity Research

Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.

Merck (MRK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $84.21, moving +0.06% from the previous trading session.

Seattle Genetics Up on Two New Oncology Deals With Merck

by Zacks Equity Research

Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.

Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug

by Zacks Equity Research

Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America

Stock Market News for Sep 15, 2020

by Zacks Equity Research

U.S. stock markets closed higher on Monday reversing some of the losses of the last week.

M&A Activities Intensify in Pharma Industry

by Zacks Equity Research

M&A Activities Intensify in Pharma Industry.

Mark Vickery headshot

No Econ Data, but Big Biopharma News

by Mark Vickery

Merck, Gilead and Lilly make progress on an otherwise slow news day.

Kinjel Shah headshot

Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals

by Kinjel Shah

AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.

Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO

by Zacks Equity Research

Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO

Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies

by Zacks Equity Research

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

Merck (MRK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $84.88 in the latest trading session, marking a +1.86% move from the prior day.

Tracey Ryniec headshot

Generation X Investors: Deja Vu?

by Tracey Ryniec

Generation X investors came of age in the dot-com boom when Microsoft and other tech titans hit new highs. Now, in 2020, it's happening again.

Merck Announces Detailed Data on Late-Stage Cough Candidate

by Zacks Equity Research

Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.

Kinjel Shah headshot

CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge

by Kinjel Shah

The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.

Kinjel Shah headshot

Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study

by Kinjel Shah

Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.

Here's Why AstraZeneca (AZN) Stock is Up This Year So Far

by Zacks Equity Research

AstraZeneca's (AZN) shares are up this year mainly due to rapid progress in its efforts to make a vaccine to treat COVID-19 as well as other positive pipeline and regulatory updates.

Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity

by Zacks Equity Research

Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.

J&J to Stop Development of Influenza Candidate Pimodivir

by Zacks Equity Research

Johnson & Johnson (JNJ) to halt the development of pimodivir, an investigational antiviral treatment of influenza A infection.

Innoviva (INVA) in Focus: Stock Moves 7% Higher

by Zacks Equity Research

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.